World
Trials now testing personalized mRNA vaccines against lung and pancreatic cancer
Trials testing mRNA vaccines for lung cancer, pancreatic cancer and other diseases are already underway, using the same approach as Intisimran vaccine, which until recently sounded like science fiction. In the process, a tumor sample is analyzed to create a vaccine tailored to its specific mutations, so each patient receives a unique drug for the cancer in their body. Last summer, Moderna and Merck announced that Intisimran passed a phase 3 trial in preventing melanoma recurrence.
· Source: Maariv. Photo as published in the article
Trials testing personalized mRNA vaccines for lung cancer, pancreatic cancer and other diseases are already underway, using an approach where each patient's tumor sample is analyzed to generate a unique vaccine for that patient's specific cancer mutations.
According to reports, trials testing mRNA vaccines for lung cancer, pancreatic cancer and other diseases are already underway. The trials use the same approach as Intisimran, which until recently sounded like science fiction.
The process involves analysis of the tumor sample to create a vaccine tailored to its specific mutations, so each patient receives a unique drug for the specific cancer in their body.
According to the full report, which was based on reporting in the Washington Post, pharmaceutical companies Moderna and Merck announced last summer that the vaccine 'Intisimran autogen' passed a phase 3 clinical trial in preventing melanoma recurrence, a result that experts celebrated as a historic breakthrough for mRNA-based cancer treatments.
Alongside the optimism, researchers warn that it may still be years before the vaccines in current trials mature into mass treatment, and they still need to prove their safety and effectiveness on a large scale.
Source: Maariv
